爱斯坦-巴尔病毒对巨细胞M2/M1迁移和EphA2表达在不良药物反应中的影响
Ran An1, Dong-Jie Sun1, Hao-Xue Lei1
1Department of Dermatology, First Affiliated Hospital of Kunming Medical University, Kunming, China.
The Journal of dermatology
|November 13, 2024
概括
埃普斯坦-巴尔病毒 (EBV) 的重新激活,可能会被甲加剧,在药物不良反应 (ADR) 中影响巨细胞极化和细胞因子配置. 增加的EphA2表达与EBV负载相关,这表明它是ADR患者EBV风险的标志物.
科学领域:
- 免疫学 免疫学 免疫学
- 病毒学 病毒学
- 皮肤病学 皮肤病学
背景情况:
- 药物不良反应 (ADRs) 像黄斑斑膜外 (MPE) 和史蒂文斯-约翰逊综合征/有毒表皮解 (SJS/TEN) 涉及复杂的免疫反应.
- 爱斯坦-巴尔病毒 (EBV) 反激活在ADRs的发病过程中的作用仍然不完全理解.
研究的目的:
- 为了研究EBV再激活的影响,与或没有德甲 (DXM),在免疫细胞和细胞因子在患有ADRs患者.
- 为了确定EBV受体EphA2表达是否影响ADRs中的EBV激活.
主要方法:
- 在ADR患者和对照中分析单细胞,M2/M1巨细胞比率和细胞因子 (IL-4,IL-13,TNF-α,IFN-γ,IFN-β,CXCL9,CXCL10) 的前性纵向研究.
- 通过H&E和EBER染色分析EBV存在的皮肤活检;与EBV +/- DXM共同培养的外周血液单核细胞.
主要成果:
- 在MPE和SJS/TEN患者的皮肤病变中检测到EBV.
- 在ADR患者中,EBV和EBV+DXM诱导了M2巨细胞的转移,并提高了IL-4,IFN-γ和CXCL9水平.
- 在单细胞中增加的EphA2表达与MPE和SJS/TEN患者的EBV病毒载量增加相关.
结论:
- 由DXM调节的EBV活性,有助于M2巨细胞极化和ADRs中的高水平的促炎细胞因子.
- 在ADR患者中,EphA2表达是EBV激活的潜在指标和风险标志物.
相关概念视频
Receptor Downregulation in MVBs
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
Allergic Drug Reactions
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing numerous...
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of many...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Drug Toxicity: Allergic Reactions
Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial exposure to a...
Drug toxicity: Drug–Drug Interaction
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...


